Sanofi S.A., FR0000120578

Sanofi reports phase 2b data: Sanofi stock sits below EUR 75 target

Published on 10/21/2026 at 10:28 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Sanofi's October 20 update covered duvakitug phase 2b data. Sanofi stock costs EUR 73.40 on October 21, 2026 before Q3 results on October 30.

Upcoming results and analyst view

Sanofi's October 20, 2026 update covered positive phase 2b duvakitug data.
Second-quarter 2026 revenue reached EUR 12.3 billion, up 15.00 percent year over year.
Sanofi stock trades at EUR 73.40 at 10:18 a.m. CEST at Lang & Schwarz on October 21, 2026.

Sanofi S.A., FR0000120578, Illustration mit AI erstellt.

Sanofi stock (ISIN FR0000120578) was trading at EUR 73.40 at Lang & Schwarz on October 21, 2026 at 10:18 a.m. CEST. On October 20, 2026, Sanofi highlighted positive long-term outcomes from new phase 2b data for duvakitug with Teva in ulcerative colitis and Crohn's disease.

Three company events since October 6

Sanofi announced on October 6, 2026 that its third-quarter 2026 results would be published on October 30, 2026, in a release linked to Sanofi. The company listed a Tour de France partnership on October 16, 2026 and an insulin manufacturing facility project in Germany on October 19, 2026, before the October 20 duvakitug update.

What does October 30 mean?

The upcoming report will test whether Sanofi can sustain the expansion visible in second-quarter 2026 revenue. Simply Wall St reported revenue of EUR 12.30 billion for the quarter, up 15.00 percent from the prior-year period, while earnings per share fell to EUR 0.29 from EUR 1.01. The contrast leaves the October report with a clear test: sales growth must translate into improved earnings quality.

Analyst caution adds a second benchmark. On October 16, 2026, RBC Capital Markets cut its price target from EUR 80.00 to EUR 75.00 and kept a Sector Perform rating, citing pressure outside Dupixent, according to Finanzen.at. Jefferies had maintained a Buy rating with a EUR 100.00 target on October 7, 2026, as reported by Markets Insider.

Dates investors can track

Sanofi's third-quarter 2026 results are scheduled for October 30, 2026, with a management presentation and question-and-answer session from 1:30 p.m. to 2:30 p.m. CET. The investor calendar also lists the Jefferies Global Healthcare Conference in London for November 17, 2026, where Vaccines executive Thomas Triomphe is scheduled to speak, according to Sanofi.

Sanofi stock stays event driven

The October update adds clinical support for the pipeline, while the earnings date and analyst target keep attention on sales conversion and profit delivery.

Sanofi was trading at EUR 73.40 at Lang & Schwarz on October 21, 2026 at 10:18 a.m. CEST.

The further course of trading is shown by the continuously updated real-time quote of Sanofi stock.